Armistice Capital LLC Purchases New Stake in Vincerx Pharma, Inc. (NASDAQ:VINC)

Armistice Capital LLC acquired a new position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned approximately 0.07% of Vincerx Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Marshall Wace LLP increased its position in shares of Vincerx Pharma by 359.1% during the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after acquiring an additional 256,967 shares in the last quarter. Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Stock Performance

Shares of NASDAQ VINC opened at $0.70 on Friday. The stock has a market cap of $20.77 million, a price-to-earnings ratio of -0.39 and a beta of 1.51. Vincerx Pharma, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $9.37. The firm’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $1.47.

Vincerx Pharma (NASDAQ:VINC) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.12. On average, sell-side analysts predict that Vincerx Pharma, Inc. will post -0.49 EPS for the current year.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.